SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Epicenter who wrote (1672)1/25/1999 4:41:00 PM
From: Michael Greene  Read Replies (1) of 10280
 
I am at a loss to understand Sepracor's strategy for its single isomer version of Meridia. The company has stated that they plan to begin clinical trials this year and will develop it without a partner. However, Knoll Pharmaceutical has just begun marketing Meridia in the past year. Don't they have a composition of matter patent that will run for many years. Can anyone enlighten me on this?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News